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Carbapenem-resistant Enterobacteriaceae (CRE) are a group of multi-drug resistant 
organisms (MDROs) that is currently considered an important and urgent public health concern 
due to their high mortality rates, antibiotic resistance, and their potential for rapid transmission. 
These pathogens are more commonly seen in healthcare-associated infections with some also 
occurring in the community. This study focused on distinguishing CRE into two distinct groups 
based on resistance mechanism: carbapenemase-producing CRE (CP-CRE) and non-CP-CRE. In 
order to determine if testing for carbapenemase can be useful in infection prevention, we aimed 
to quantify the total hospitalization in days per patient within a 90-day follow-up period after 
carbapenemase test results were available for both of the CP-CRE and non-CP-CRE patient 
groups, using the statewide hospitalization and CRE surveillance data from the 2017 calendar 
year, provided by the Connecticut Hospital Association and the Connecticut Department of 
Public Health (CT DPH). The study sample consisted of a total of 126 patients (32 CP-CRE, 94 
non-CP-CRE). Adjusting for age and sex, we found that CP-CRE patients had 31.6% fewer 
hospitalization days than non-CP-CRE patients (P<0.0001). We also found that the number of 
distinct hospitalizations per patient in each group while controlling for age and sex was not 
statistically significant (P=0.3250). Our results suggest that carbapenemase testing can be 
informative in possibly guiding treatment or cohorting patients, but further studies with a greater 
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I. Introduction 
 Multi-drug resistant organisms (MDROs) have been a major public health issue ever 
since the first widespread use of antibiotics starting with penicillin in the 1940s. These 
microorganisms are resistant to one or more classes of antimicrobials, making it difficult to 
provide effective treatment1. One method in which drug resistance develops is through antibiotic 
selective pressure, where previous drug exposure or incomplete or inadequate treatment 
regimens may select for a particular favorable mutation that allows for the microorganism to 
persist2, 3. Drug resistance can also be acquired through the exchange of genetic material, where 
genes that confer resistance to a particular antibiotic are transferred from one microorganism to 
another, most commonly mediated through plasmids2. This mechanism is especially concerning 
since resistance can even be transferred between different types of bacteria through these 
plasmids, which may frequently carry resistance genes against more than one antibiotic class, 
such as fluoroquinolones or aminoglycosides4. 
 One particular subset of MDROs known as carbapenem-resistant Enterobacteriaceae 
(CRE) are a group of Gram-negative bacteria of great public health concern due to their high 
levels of antibiotic resistance and potential for rapid transmission. Enterobacteriaceae, such as 
Escherichia coli and Klebsiella pneumoniae, are normally a component of the intestinal 
microbiota, but are also one of the most common causes of infection in both the community and 
healthcare settings, leading to various illnesses such as urinary tract infections (UTIs), 
septicemia, pneumonia, meningitis, etc.5 CRE infections are mostly prominent in healthcare 
settings where there are vulnerable individuals at risk due to being immunocompromised, 
experiencing various other comorbidities, receiving indwelling catheters, or undergoing invasive 
procedures. In a meta-analysis conducted by van Loon et al. (2018), several of the greatest risk 
 2 
factors associated with acquiring CRE included the use of medical devices, previous antibiotic 
use, invasive procedures, and ICU admissions4. 
CRE infections are also a growing concern since carbapenems (which include doripenem, 
meropenem, imipenem, and ertapenem) are one of the broadest spectrum class of antibiotics 
available and are typically used as a last resort treatment in combatting antibiotic-resistant Gram-
negative infections5, 6. Carbapenems are part of the beta-lactam class of antibiotics, which 
function by disrupting proper bacterial cell wall synthesis5, 7. They are a relatively new class of 
drugs developed in response to increasing resistance seen against other therapy options7. 
Therefore, these drugs are highly important in treating a wide variety of healthcare-associated 
infections5. However, due to carbapenem resistance and the lack of development of new 
effective drugs, possible treatment options become incredibly limited5, 8. Additionally, there is 
increasing concern of potential spread of carbapenem resistance into the community or into other 
organisms9. 
This concern is also exacerbated by the presence of carbapenemase-producing CRE (CP-
CRE), which is distinct from non-CP-CRE due to their contrasting resistance mechanisms. Non-
CP-CRE have resistance mechanisms comprised of beta-lactamase enzymes (AmpC or 
Extended-spectrum beta-lactamase) in addition to porin mutations that prevent proper drug 
penetration or the formation of efflux pumps that actively transport drugs out of the organism7, 9, 
10. On the other hand, as their name implies, CP-CRE are able to produce carbapenemases which 
directly break down carbapenems in addition to many other beta-lactam molecules5, 11. These 
enzymes are often encoded on mobile genetic elements (typically plasmids), and therefore can 
contribute to rapid spread of resistance among Enterobacteriaceae and even other types of Gram-
negative bacteria9, including naïve bacteria that may never have had any prior exposure to 
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carbapenems12. Additionally, the majority of existing beta-lactamase inhibitors, including 
clavulanic acid, are not effective against carbapenemases13, which makes it difficult to work 
around carbapenemase-mediated resistance. Recently, novel beta-lactam/beta-lactamase inhibitor 
combinations, such as ceftazidime/avibactam, have been shown to be effective against certain 
types of carbapenemases, including Klebsiella pneumoniae carbapenemases (KPC)6, 14. 
However, occurrences of resistance against even these newer therapy options have already been 
observed15, 16, adding to the growing concerns of effectively treating carbapenemase-mediated 
resistance. In general, these enzymes are believed to contribute to the overall rapid spread of 
resistance, result in high mortality rates, and are responsible for the overall increase in CRE in 
the United States10. In the US, the first CP-CRE isolate was identified in 1996 and in a relatively 
short period of time every state (with the exception of Idaho and Maine) has had at least one 
report of CP-CRE as of 20159. This highlights the swift spread of carbapenemase-mediated 
resistance and emphasizes the specific need to address CP-CRE transmission and prevention. 
In order to target CP-CRE, it is important to be able to discern the two resistance 
mechanisms in an efficient and timely manner. However, it has been difficult developing criteria 
based on drug susceptibility patterns that are able to correctly distinguish the two groups due 
their overlapping antibiotic susceptibility profiles9. The CDC’s CRE phenotypic surveillance 
definition (2015) has lower specificity for CP-CRE, particularly in areas with low burdens of 
infection9. In Connecticut, surveillance for CRE has been implemented since 2014 based on a 
phenotypic case definition and was made a laboratory reportable condition (although 
carbapenemase testing was fairly limited in the clinical laboratories at this time). With a revised 
and less complicated case definition, mandatory submission of all CRE isolates, and the 
availability of advanced molecular testing at the CT State Public Health Laboratory (CT SPHL) 
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in 2017, every identified CRE case is able to be genetically characterized, elucidating the 
mechanism of resistance and allowing for earlier identification of outbreaks and more timely 
initiation of investigations, screening of potentially exposed individuals, and a greater 
understanding of the epidemiology of CRE in healthcare settings across the state17. 
Carbapenemase testing becomes especially helpful to make a conclusive distinction in patients’ 
diagnoses and for surveillance; however, it is not widely used as it is not currently recommended 
for guiding treatment regimens as well as limited laboratory capabilities10. This has further 
implications with regards to infection prevention procedures as individuals with CRE infections 
are generally placed on contact precautions for prolonged periods of time. Contact precautions 
refer to proper hand hygiene, gloves, gowns, single rooms, and environmental and equipment 
cleaning in order to avoid direct or indirect physical transmission of the pathogen9, 18. In 
conjunction with single patient rooms, contact precautions can greatly limit the spread of 
microorganisms to other susceptible individuals within the healthcare facility18. However, the 
use of single patient rooms for every infected or colonized CRE patient can present logistical 
challenges for many healthcare facilities. As an alternative option, healthcare professionals may 
consider cohorting of CRE-positive patients in multi-occupancy rooms so that there is greater 
availability of hospital rooms for other patients (although it is important to emphasize that 
contact precautions should be implemented for each individual patient within the cohort). 
Furthermore, there are currently no set guidelines for discontinuing transmission-based 
precautions since there is a limited number of studies that address this issue19. This is important 
to establish since prolonged contact precautions can be difficult for healthcare professionals, 
strains resources, and potentially leads to unfavorable outcomes regarding patients’ quality of 
care20, although this remains an on-going debate as some studies show no significant difference 
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in adverse outcomes21. There is additional difficulty in establishing these guidelines and 
determining procedures for discontinuing precautions since the length of CRE colonization or 
carriage can be long and varied, and generally has not been well-studied in patients who are 
hospitalized or readmitted22. According to the Society for Healthcare Epidemiology of America 
(SHEA) Expert Guidance document (2018), it is recommended that discontinuation of contact 
precautions for non-CP-CRE infections be determined on a case-by-case basis depending on the 
last positive culture, presence of a clinical infection, current antibiotic use, and screening culture 
results19. For CP-CRE, both the CDC CRE toolkit (2015) and the 2018 SHEA guidance 
document recommend contact precautions to be indefinitely maintained19, 22. 
By utilizing these recommendations in conjunction with carbapenemase testing, there is 
potential to allow for improved decision-making and efficiency with regards to the use and 
prioritization of contact precautions and cohorting of affected individuals, especially in high 
CRE burden areas where there may be limited resources and availability of single patient rooms. 
Carbapenemase testing can help improve the control and spread of CRE by helping to distinguish 
patients based on their resistance mechanisms and may assist with the efficient use of hospital 
resources and available space. For instance, healthcare professionals may decide to distinguish 
CP-CRE and non-CP-CRE patients and group them separately rather than use single rooms for 
each individual or cohorting them together as one CRE group and unknowingly risking the 
transmission of carbapenemase-mediated resistance to non-CP-CRE infected patients. This study 
is designed to quantify the total length of hospitalization in days for patients with either CP-CRE 
infections or with non-CP-CRE infections in the state of Connecticut from the time of diagnosis 
using the CT SPHL results. Ultimately, this study can potentially provide some insight on the 
practicality of carbapenemase testing in elucidating how to prioritize patients and inform 
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decisions for contact precautions and cohorting. The study also aims to characterize the two 
patient groups in order to determine if there are fundamental differences that may contribute to 
the likelihood of having a certain type of infection. I hypothesize that patients with CP-CRE will 
have a greater number of total hospitalization days over a period of 90 days following CRE 
identification than patients with non-CP-CRE, as a result of extremely limited treatment options 
for CP-CRE infections which may contribute to a reduced rate of recovery and more serious 
outcomes that may prolong hospitalization stay. 
II. Methods 
This study was conducted using the Connecticut Department of Public Health’s (CT 
DPH) CRE surveillance data and the Connecticut Hospital Association’s CHIME hospitalization 
data (which was shared for use by CT DPH) for the 2017 calendar year. A case-control design 
was used where controls consisted of individuals with non-CP-CRE diagnoses and cases 
consisted of individuals with CP-CRE diagnoses. CP-CRE was determined based on 
carbapenemase production (phenotypic mCIM) and antibiotic susceptibility results provided by 
the CT SPHL. Additionally, CHIME hospitalization data for the 2016 calendar year and state 
death certificate data for the 2017 calendar year were utilized as a part of the analysis comparing 
the CP-CRE and non-CP-CRE groups. 
Individuals were included in this study if they had a clinical isolate submitted to the CT 
SPHL and had a non-missing laboratory isolate receipt date for the calendar year 2017 (Figure 
1). From this group, individuals with missing phenotypic mCIM results and inconclusive 
carbapenem susceptibility results were excluded. Individuals with positive phenotypic mCIM 
results were considered to have CP-CRE regardless of their carbapenem susceptibility profiles. 
On the other hand, individuals with negative phenotypic mCIM results that were non-susceptible 
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to one or more carbapenems were classified as non-CP-CRE. Individuals with isolates that were 
found to be susceptible to all four carbapenems at the CT SPHL were classified as non-CP-non-
CRE organisms. However, this group of isolates were classified together with the non-CP-CRE 
for this analysis due to the assumption that the hospitals would have viewed the individuals as 
CRE-positive patients and were selected for CT SPHL isolate submission based on a carbapenem 
resistant result at the clinical laboratory. A data merge was performed by creating a Cartesian 
Product between the CRE and the CHIME inpatient hospitalization data using each of the 
patient’s first four letters of their first and last names, date of birth, and sex. A Cartesian Product 
was used so all possible combinations of the CRE cases and hospitalizations are matched (rather 
than arbitrary matching of a single hospitalization to a case). In order to maintain a consistent 
follow-up period, patients with isolates that were received by the CT SPHL between 1/1/2017 
through 10/2/2017 were used in the analysis so that every individual had a 90-day follow-up 
period in calendar year 2017. 
 
Figure 1. Flow chart of merging process of the 2017 CRE and CHIME datasets. 
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The total hospitalization in days per patient was calculated as the sum of all of the lengths 
of stay that each patient had after their first CRE was identified. Depending on if they had one 
index hospitalization or multiple subsequent hospitalizations due to readmissions, the length of 
stay for the first index hospitalization was calculated from the point of diagnosis (which was 
assumed for consistency purposes to be the date in which the isolate was received by the CT 
SPHL) to the discharge date. The length of stay for a subsequent hospitalization due to 
readmission (if the patient had any) was calculated from the admission date of that particular 
hospitalization to the discharge date. Additionally, the number of distinct hospitalizations post-
diagnosis was determined for each patient. Comparisons between the CP-CRE and non-CP-CRE 
groups were made for age, sex, race/ethnicity, organism, specimen source, prior hospitalization, 
and death within 90 days. Prior hospitalizations were determined by using the CHIME 
hospitalization data for the 2016 calendar year and merging to those patients with isolates from 
2017. Finally, death within the 90-day follow-up period was examined by utilizing the 2017 state 
death certificate data and determining if the date of death occurred within the follow-up period.  
The Wilcoxon-Mann-Whitney test, chi-square test, and Fisher’s exact test were used to 
make comparisons between the CP-CRE and non-CP-CRE groups. A Poisson regression analysis 
was conducted to determine the association between carbapenemase diagnosis and (1) total 
hospitalization in days per patient; (2) number of hospitalizations per patient. The analysis was 
also adjusted for age and sex. Data management, cleaning, and analysis were conducted using 






i. Study population 
In the 2017 calendar year, there was a total of 293 reported CRE cases and over 1.7 
million hospitalizations in Connecticut. Out of these CRE cases, 220 had state lab diagnostic 
testing results regarding carbapenemase production and antibiotic susceptibility. By considering 
only inpatient settings, the number of hospitalizations during the study period was reduced to 
361,075. After the data merging process was completed and patients were matched with their 
corresponding hospitalizations, there was a total of 166 patients (40 CP-CRE, 126 non-CP-CRE) 
with reported cases throughout the 2017 calendar year. There were no patients that experienced 
isolates with different carbapenemase statuses or patients that changed status (i.e., from non-CP-
CRE to CP-CRE, or vice versa). After including only patients with cases between 1/1/2017 
through 10/2/2017 in order to allow for complete 90-day follow-up periods for each patient, a 
total of 126 patients (32 CP-CRE, 94 non-CP-CRE) were included in the analysis. 
ii. Comparison of CP-CRE and Non-CP-CRE patient characteristics 
CP-CRE and non-CP-CRE patients were generally uniformly represented across age and 
sex (Table 1). The median age for CP-CRE patients was slightly greater at 71.5 years whereas 
the median age for non-CP-CRE patients was 68.0 years, but this was not statistically significant 
(P=0.4047). Both study groups had approximately equal representation of female and male 
patients (P=0.7601). A significant association exists between race/ethnicity and carbapenemase 
diagnosis, where non-CP-CRE patients were more likely to be non-Hispanic White and CP-CRE 
patients were more likely to be Hispanic (P=0.0295). There was also a significant association 
between organism type and carbapenemase diagnosis, where CP-CRE patients were more likely 
to be diagnosed with K. pneumoniae isolates while non-CP-CRE patients were more likely to 
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have E. cloacae isolates (P<0.0001). The specimen source was also examined for its association 
with carbapenemase status, but was not found to be statistically significant (P=0.9783). There 
were no significant associations found between carbapenemase status and death within 90 days 
(P=0.8578) or carbapenemase status and prior hospitalizations in the 2016 calendar year 
(P=0.8403). 
Table 1. Comparison of the CP-CRE and Non-CP-CRE patient groups. 
 CP-CRE (n=32) Non-CP-CRE (n=94) P value 
Age (median, IQR) 71.5 (59.0-79.5) 68.0 (48.0-79.0) 0.40471 
Under 65 10 (31.25%) 41 (43.62%) 0.21832 
65 and over 22 (68.75%) 53 (56.38%)  
Sex   0.76012 
Female 15 (46.90%) 47 (50.00%)  
Male 17 (53.10%) 47 (50.00%)  
Race/Ethnicity   0.02953 * 
Non-Hispanic White 16 (50.00%) 66 (72.53%)  
Non-Hispanic Black   4 (12.50%) 12 (13.19%)  
Hispanic 10 (31.25%)   9 (9.89%)  
Other, Non-Hispanic   2 (6.25%)   4 (4.40%)  
Organism   <0.00013 * 
Enterobacter cloacae   4 (12.50%) 53 (56.99%)  
Klebsiella pneumoniae 24 (75.00%) 16 (17.20%)  
Escherichia coli   3 (9.38%) 14 (15.05%)  
Other   1 (3.13%) 10 (10.75%)  
Specimen Source   0.97833 
Urine 17 (60.71%) 48 (53.93%)  
Blood   3 (10.71%)   9 (10.11%)  
Respiratory   3 (10.71%) 14 (15.73%)  
Wound/Bone/Skin   1 (3.57%)   5 (5.62%)  
Other   4 (14.29%) 13 (14.61%)  
Prior hospitalization   0.84032 
Yes 17 (53.13%) 48 (51.06%)  
No 15 (46.88%) 46 (48.94%)  
Death within 90-day period   0.85782 
Yes   6 (18.75%) 19 (20.21%)  
No 26 (81.25%) 75 (79.79%)  
Note: Total number of patients and percentages in each group may not sum due to missing data and rounding. 








Table 2. Poisson regression analysis of the association between carbapenemase diagnosis and 











days per patient 
(median) 












0 22 (68.75%) 56 (59.57%)     
1   6 (18.75%) 19 (20.21%)     
2 or more   4 (12.50%) 19 (20.21%)     
1Adjusted for age and sex  
 
iii. Total hospitalization days and number of hospitalizations per patient 
The median number of total hospitalization days per patient among the CP-CRE and non-
CP-CRE groups were 3.5 and 7.0 days, respectively (Table 2). In the unadjusted Poisson 
regression examining the role of carbapenemase diagnosis on total hospitalization days, CP-CRE 
patients had 37.8% fewer hospitalization days than non-CP-CRE patients (P<0.0001). 
Controlling for age and sex results in a slightly reduced but still significant difference, where CP-
CRE patients had 31.6% fewer hospitalization days than non-CP-CRE patients (P<0.0001). 
When examining the number of distinct hospitalizations per patient in each group while 
controlling for age and sex, there was no significant difference between CP-CRE and non-CP-
CRE patients (P=0.3250). 
IV. Discussion 
i. Differences in Race/Ethnicity, Organism between CP-CRE and Non-CP-CRE patients 
 
 In our comparison of the two patient groups, CP-CRE patients were more likely to be 
Hispanic, making up 31.25% of the CP-CRE group in this study (Table 1). This is especially 
interesting since the Hispanic population in Connecticut is approximately 16.13%, according to 
the National Center for Health Statistics (NCHS) Annual State-level Age, Sex, Race, Hispanic 
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Ethnicity estimates (July 2017)23. The proportion of Hispanic individuals in the CP-CRE study 
group is almost twice the proportion of Hispanic individuals in Connecticut, which raises 
questions regarding specific risk factors or other characteristics for this particular group of 
patients. Although the small number of individuals in our study limit proper extrapolation of the 
results, it would be informative to further investigate race/ethnicity to determine if Hispanic 
individuals are truly disproportionately affected by CP-CRE and what may contribute to this 
difference. 
 Additionally, our comparison also indicated that CP-CRE patients were more likely to 
have K. pneumoniae isolates, which is a major cause of both community and hospital-associated 
infections, especially with the presence of carbapenemases9, 24. On the other hand, non-CP-CRE 
patients were more likely to have E. cloacae complex isolates, which have become problematic 
in healthcare settings, especially for individuals on mechanical ventilation25. A study further 
investigating healthcare exposures would be informative to determine if there are specific 
procedures that contribute to a greater risk of acquiring a particular type of CRE (with regards to 
both organism and resistance mechanism). 
ii. Difference in total hospitalization days for CP-CRE and Non-CP-CRE patients 
Interestingly, there is a difference in total hospitalization days between the two study 
groups where CP-CRE patients appear to have fewer hospitalization days, even after adjusting 
for age and sex (Table 2). This result contrasts with our initial hypothesis that CP-CRE patients 
would have a greater number of hospitalization days due to limited treatment options that may 
impede recovery and potentially lead to other serious outcomes. Additionally, some studies even 
suggest that CP-CRE can be more virulent26, which can imply a longer hospitalization stay if the 
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infected individuals are more ill. As for our particular study, there are a few possibilities to 
explain our results. 
 According to a study comparing mortality outcomes between CP-CRE and non-CP-CRE 
patients by Tamma et al. (2017), the investigators found that CP-CRE patients had 
approximately 4 times greater odds of mortality within a 14-day period and 3 times greater odds 
within a 30-day period than non-CP-CRE patients after adjusting for severity of illness, 
underlying comorbidities, and type of antibiotic treatment26. Greater virulence and risk of 
mortality may contribute to a shorter length of hospitalization for CP-CRE patients if they expire 
at a higher rate than non-CP-CRE patients. Further investigation incorporating both length of 
hospitalization and mortality outcomes would be important to study and informative in 
supporting this particular idea. However, when death outcomes were examined for our particular 
study, there was no significant difference between the two groups, suggesting that the rate at 
which patients expire may not be the underlying cause of the difference in total hospitalization 
days. The exact occurrence of death can be explored in order to see if timing of deaths differ 
between the two groups. Additionally, an unpublished mortality analysis conducted by the CDC 
using the Multi-Site Gram-negative Surveillance Initiative (MuGSI) data found higher rates of 
mortality in non-CP-CRE patients (communication with M. Maloney, CT DPH), which contrasts 
with results from Tamma et al. The difference in results in these studies may further imply that 
death rates may not be related with the total length in hospitalization; however, it would be more 
practical to see if similar results are obtained in other states, especially those with greater burden 
of CRE, before making any conclusive statements. 
 Another possibility explaining our results that would need further investigation is the use 
of various types of antibiotic treatment regimens. The same study by Tamma et al. reported that 
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CP-CRE patients were less likely than non-CP-CRE patients to be given active empiric antibiotic 
treatments, although this was not statistically significant26. The authors define active empiric 
treatment as consisting of at least one antibiotic given within 24 hours from the time that the first 
positive blood culture was obtained26. On the other hand, active directed antibiotic treatment was 
defined as consisting of at least one antibiotic given after antibiotic susceptibility testing results 
are available and up to 7 days after the first positive blood culture was obtained26. Despite there 
being no significant difference in the use of empiric therapy between the two groups in the 
Tamma et al. study, it is an important factor to consider for the patients in Connecticut. Since 
empiric therapy is primarily based on clinician experience and non-CP-CRE patients were more 
likely to initially receive this type of therapy, this patient group may be experiencing greater 
exposure to various antimicrobial drugs that may potentially be ineffective and causing 
weakened immune states with disruptions to patients’ commensal bacteria. This can contribute to 
longer lengths of hospitalizations for non-CP-CRE patients which can increase the possibility in 
which these patients may acquire other infections and the chance of developing additional 
resistance during their stays. 
 The reasons for hospital admission may be interesting to explore as a possible 
explanation for the difference in total hospitalization days. The primary reason for hospital 
admission of CP-CRE patients may have been directly due to the CP-CRE infection. On the 
other hand, the non-CP-CRE patients may have been initially admitted due to another underlying 
condition and the CRE diagnosis was a secondary or subsequent event. Due to a potential 
difference in underlying conditions or primary reason of hospitalization, this may possibly result 
in a longer hospitalization for non-CP-CRE patients. One of the major limitations of this 
particular study is that we were unable to investigate comorbidities and primary causes of 
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admission; however, this would be another crucial aspect of further research that should be 
conducted to learn more about these two groups. It would also be important to study 
hospitalization exposure in both the previous calendar year and prior to carbapenemase diagnosis 
in order to give an indication of the extent of prior hospital exposure and learn of any differences 
that may exist between the two groups. It is suggested that carbapenem resistance mechanisms 
are acquired in different ways for the CP-CRE and non-CP-CRE organisms, and this may 
contribute to different risk factors for patient acquisition27. Although more evidence is necessary, 
some of the data suggest that non-CP-CRE organisms are believed to primarily acquire their 
resistance through antibiotic exposure and clonal expansion, while CP-CRE organisms obtain 
their resistance through horizontal transfer (without necessarily having previous antibiotic 
exposure)12, 27. In a future study, it would be interesting to examine both prior hospitalizations 
and antibiotic exposures to see if these factors may explain why the non-CP-CRE group have 
longer hospitalizations than CP-CRE patients. It may also be informative to scrutinize the period 
between hospital admission and CRE diagnosis in order to determine if the CRE was a cause of 
admission or attributed to hospital exposures. Only prior hospitalizations in the previous calendar 
year (2016) were able to be examined for this study, but no statistically significant association 
was found. 
Lastly, an alternative theory in explaining the difference in hospitalization days between 
the two patient groups may be attributed to the type of culture (surveillance or clinical). 
Although the isolates in Connecticut’s CRE surveillance system should all represent clinical 
cultures (according to surveillance and submission guidelines), there are potentially some 
isolates that were collected from patients without clinical infection. It may be the case that some 
of the CP-CRE patients may have been identified through surveillance cultures rather than 
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clinical cultures, indicating that colonization of these patients was being picked up and they may 
not actually have been infected or sick. Asymptomatic colonization can contribute to a shorter 
hospitalization period compared to the non-CP-CRE patients. For a future study, differences in 
surveillance and clinical cultures should be an important aspect to explore between the two 
groups to determine if this is true. 
iii. Potential implications in infection control and cost 
Although this study has several limitations and has additional factors to investigate, the 
current results indicate that the difference in hospitalization days between CP-CRE and non-CP-
CRE patients advocates for the importance in distinguishing carbapenemase status among CRE 
patients in order to possibly cohort individuals with similar infection types. The investigators of 
the previously mentioned study describing differences in mortality outcomes between the two 
patient groups also agree that distinguishing the carbapenem resistance mechanism is necessary 
to allow for improved treatment decisions26. Many hospitals and other healthcare facilities are 
limited in their resources and laboratory capabilities to distinguish the carbapenem resistance 
mechanisms26. There are also very few studies that that have provided strong evidence 
suggesting to do so26. As a result, healthcare facilities typically manage CRE patients as one 
general group using the same infection control procedures regardless of resistance mechanism. 
These procedures include contact precautions and the use of single patient rooms, which may not 
be realistic in many hospitals due to limited resources. Cohorting of patients and even cohorting 
of healthcare professionals may be additionally used as a way of conserving resources. However, 
in light of the results of this and Tamma et al. studies, there is a great concern of mixing patients 
with CRE with different resistance mechanisms who have significantly different outcomes. This 
unnecessarily exposes some patients to greater risks for worse clinical outcomes if cohorting of 
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both CP-CRE and non-CP-CRE patients together unknowingly occur. Additionally, as observed 
in this study, there are instances where the clinical labs would diagnose some patients to be non-
CP-CRE, but the state lab determines some individuals to actually have non-CP-non-CRE 
organisms due to differing antibiotic susceptibility profiles. However, from the hospital’s 
standpoint, a non-CP-non-CRE patient is treated under the assumption that they have a CRE 
organism since it takes time for state lab results to inform the clinical labs. Consequently, these 
patients would be at risk of receiving incorrect/inadequate treatment or at risk of acquiring a 
CRE organism if they are cohorted with other non-CP-CRE patients. 
Ideally, it would be best if cohorting was utilized based on resistance mechanism and 
perhaps even organism type so that resistance profiles are less likely to be mixed. In particular, 
CP-CRE pose a greater need to separate out from non-CP CRE since their carbapenemase 
resistance genes are encoded on mobile genetic elements and are associated with a relatively low 
fitness cost to the organisms, making them readily transmissible and retained12. Through this 
method, naïve non-CP-CRE have the potential to gain the ability to survive against drugs that 
they may never have previously been exposed to12. This would further limit effective treatment 
options for these patients, putting them in a more difficult situation with potentially worse 
outcomes. It would also be helpful to use carbapenemase testing to distinguish patients with CP-
CRE so that they can be appropriately prescribed new drug options when they become 
available26. Although development of new drugs against CP-CRE have been slow5, 8, it is 
suggested that these treatments be strictly reserved for patients with confirmed CP-CRE 
organisms26. Prioritizing CP-CRE patients for these new treatments and cohorting based on 
carbapenemase activity can possibly allow for better control over any resistance that may 
develop with the use of these drugs and keep it from spreading to all CRE. Carbapenemase 
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testing can help to improve prescribing decisions and prevent non-CP-CRE patients from being 
unnecessarily exposed to these novel antibiotics that should have been reserved for those with 
true carbapenemase activity. 
Due to differences in patient mortality outcomes26 and potentially total hospitalization 
days (from this study) between CP-CRE and non-CP-CRE patients, carbapenemase testing has 
the potential to be beneficial for cohorting and treatment decisions. Carbapenemase testing can 
be costly and resource-intensive for hospitals if conducted on-site in their clinical laboratories; 
however, the benefits of carbapenemase testing may outweigh the costs of managing CRE 
infections, especially in high burden areas. This cost would generally be associated with the 
components of contact precautions, which include gowns, gloves, time delegated to put on/off 
the protective wear, environmental/equipment cleaning, and the use of single patient rooms, 
which takes away from available space and time for addressing other patients. There are also 
clinical costs associated with patient isolation that should be considered, as adverse outcomes 
have been studied, such as decreased or delayed healthcare worker contact, lower patient 
satisfaction, and greater non-infectious events, depression, and anxiety20. However, it is 
important to note that there is on-going debate on whether or not adverse outcomes are 
associated with patient isolation procedures as it is difficult to have definitive studies with 
comparable control groups without jeopardizing the safety and care of these patients20. 
Additionally, there may be publication bias toward studies associating contact precautions with 
unfavorable outcomes20. 
There are currently no studies investigating the costs of CP-CRE and non-CP-CRE 
infections, but there are a few that attempt to model the economic burden of certain multi-drug 
resistant infections. One particular model examined the cost of CRE infections, although the 
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investigators did not distinguish between CP-CRE and non-CP-CRE infections28. The 
investigators found that the cost of a single CRE infection (regardless of the type of infection, 
which included bacteremia, intra-abdominal, pneumonia, complicated urinary tract infection) 
from the hospital perspective was about $29,157. Costs from the hospital perspective consisted 
of the opportunity cost of lost bed days due to the additional length of stay attributable to the 
CRE infection28. Based on this model, CRE infections generally can be quite costly and as a 
result, it would be of the utmost importance to determine whether the benefit of carbapenemase 
testing would outweigh the cost of managing CRE infections as one general category. With 
carbapenemase testing, there would be opportunities to cohort patients based on their resistance 
mechanisms and free up single-occupancy rooms and bed space to other types of patients. 
Alternatively, CP-CRE patients can be prioritized for single-occupancy rooms. In especially high 
burden settings, carbapenemase testing can possibly aid with discontinuation of precautions if 
these facilities need to conserve resources and reduce costs by prioritizing CP-CRE patients and 
continuing them on contact precautions while deciding on a case-by-case basis if discontinuation 
of precautions should occur for non-CP-CRE patients (as the 2018 SHEA guidance document 
suggests)19. While it is typical to implement contact precautions for all CRE patients, there may 
be some facilities in high burden areas that would seriously need to consider prioritizing certain 
types of patients. 
V. Conclusions 
There are several limitations associated with this study. Due to the limited sample size, 
this study may not have had the necessary power to detect a significant difference, making it 
difficult to generate any conclusive remarks about the two patient groups. Furthermore, this 
study was conducted using Connecticut state data; therefore, the results may not be appropriately 
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interpretable for other states, especially those with contrasting CRE prevalence and incidence 
rates. Mortality outcomes for this study was conducted using the addition of the state death 
registry, which is separate from the CHIME hospitalization and CRE surveillance datasets used 
for the other analyses. Lastly, comorbidities and other MDROs were unable to be adjusted for in 
our analyses due to limitations in the available information. A future study investigating similar 
outcomes and addressing all of these limitations would be an ideal and potentially informative 
next step to take. 
 In conclusion, our study indicates that there is a significant association between 
carbapenemase diagnosis and total hospitalization days, where CP-CRE patients were associated 
with having fewer hospitalization days than non-CP-CRE patients. The direction of this 
association contrasts with a different study comparing mortality outcomes between the two 
patient groups, where CP-CRE patients were unfavorably at greater odds of dying than non-CP-
CRE patients. Nevertheless, there appears to be a preliminary consensus that there are significant 
differences in clinical outcomes between CP-CRE and non-CP-CRE patients, which suggest that 
carbapenemase diagnostic testing has the potential to be useful in improving the care of these 
patients. Additional studies that specifically distinguish CP-CRE and non-CP-CRE infections 
need to be conducted in order to make definitive conclusions to ultimately improve the care of 
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